First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation TrustZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical developmentZIMA-101 ...
Century Therapeutics (IPSC) downgraded to Hold after CNTY-101 halted and slow clinical progress. Click here to read my most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results